Status:
TERMINATED
Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.
Lead Sponsor:
University of Toledo Health Science Campus
Collaborating Sponsors:
ElectroCore INC
Conditions:
Raynaud Phenomenon
Primary Raynaud Phenomenon
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Raynaud's phenomenon (RP) is a common vascular disorder that affects approximately 10% of the general population. RP is associated with significant morbidity that may include loss of the digits due to...
Detailed Description
Raynaud's phenomenon (RP) is a common vascular disorder that that affects approximately 10% of the general population. RP causes some areas of the body (i.e. fingers and toes) to feel cold and numb in...
Eligibility Criteria
Inclusion
- • Clinical Diagnosis of Primary Raynaud's Phenomenon
Exclusion
- Less than 18 years of age
- Pregnant women
- Current smokers
- Have Digital ulcers
- Diagnosed Pulmonary hypertension
- Currently on vasodilators (i.e. Phosphodiesterase type 5 inhibitors, prostacyclin, nitroglycerine, or other nitric oxide derivatives)
- Currently on Calcium Channel Blockers
Key Trial Info
Start Date :
April 30 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 27 2020
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT03869008
Start Date
April 30 2019
End Date
February 27 2020
Last Update
July 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Unversity of Toledo Medical Center
Toledo, Ohio, United States, 43614